logo BDSP

Base documentaire


Votre avis nous intéresse

Le réseau BDSP met en oeuvre un projet d'innovation et d'amélioration de ses services, dans le souci constant de proposer des contenus de qualité adaptés aux besoins des utilisateurs.

Identifier de nouvelles sources de financements est la condition nécessaire pour assurer la poursuite et la pérennité de cet outil unique qu'est la BDSP, tout en le faisant évoluer.

Pour définir un nouveau modèle économique, nous avons besoin de votre avis : merci de répondre à notre enquête (temps estimé : 5 minutes).

Participer maintenant
Participer plus tard J'ai déjà participé

  1. SSRI-induced sexual dysfunction : Fluoxetine, paroxetine, sertraline, and fluvoxamine in a prospective, multicenter, and descriptive clinical study of 344 patients.

    Article - En anglais

    The authors analyzed the incidence of sexual dysfunction (SD) with different selective serotonin reuptake inhibitors (SSRIs ; fluoxetine, fluvoxamine, paroxetine, and sertraline) and hence the qualitative and quantitative changes in SD throughout time in a prospective and multicenter study.

    Outpatients (192 women and 152 men ; age=39.6±11.4 years) under treatment with SSRIs were interviewed with an SD questionnaire designed for this purpose by the authors and that included questions about the following : decreased libido, delayed orgasm or anorgasmia, delayed ejaculation, inability to ejaculate, impotence, and general sexual satisfaction.

    Patients with the following criteria were included : normal sexual function before SSRI intake, exclusive treatment with SSRIs or treatment associated with benzodiazepines, previous heterosexual or self-erotic current sexual practices.

    Excluded were patients with previous sexual dysfunction, association of SSRIs with neuroleptics, recent hormone intake, and significant medical illnesses.

    There was a significant increase in the incidence of SD when physicians asked the patients direct questions (58%) versus when SD was spontaneously reported (14%). There were some significant differences among different SSRIs : paroxetine provoked more delay of orgasm or ejaculation and more impotence than fluvoxamine, fluoxetine and sertraline (X2, p<. 05).

    Only 24.5% of the patients had a good tolerance of their sexual dysfunction. (...)

    Mots-clés Pascal : Fluoxétine, Paroxétine, Sertraline, Fluvoxamine, Incidence, Epidémiologie, Toxicité, Chimiothérapie, Traitement, Trouble comportement sexuel, Etude multicentrique, Sexe, Homme, Antidépresseur, Psychotrope, Inhibiteur recapture, Sérotonine

    Mots-clés Pascal anglais : Fluoxetine, Paroxetine, Sertraline, Fluvoxamine, Incidence, Epidemiology, Toxicity, Chemotherapy, Treatment, Sexual behavior disorder, Multicenter study, Sex, Human, Antidepressant agent, Psychotropic, Reuptake inhibitor, Serotonin

    Logo du centre Notice produite par :
    Inist-CNRS - Institut de l'Information Scientifique et Technique

    Cote : 97-0468789

    Code Inist : 002B02U06. Création : 03/02/1998.